Agios Pharmaceuticals (0HB0.L) Stock Price
$39.6 8.2%
to add to portfolio
AI Score
-
Alternative
7 -
Fundamental
8 -
Technical
6
Our AI score evaluates a company's performance on a scale from 0 to 10 by analyzing alternative data points — web traffic, app downloads, job postings, etc - along with financial health and technical signals. Scores below 4 project bearish performance, while scores above 6 project bullish performance.
Sign up to get access to more historical data and insights on Agios Pharmaceuticals, AI stock picks, stock alerts and much more.
0HB0.L AI Stock Analysis
AI stock analysis for 0HB0.L is missing at the moment.
Our AI stock analysis reviews financial data, technical analysis, and alternative data insights to project stock performance. For example, analyzing a company like Agios Pharmaceuticals (0HB0.L) provides a clear summary of future projections. Gain the edge you need to make confident, data-driven investment decisions.
Sign up and become a member to get access to AI stock analysis.
Sign up
Agios Pharmaceuticals (0HB0.L) Price Prediction
Based on a combination of financial analysis, technical indicators, and insights from alternative data, we predict that the stock price of Agios Pharmaceuticals (0HB0.L), currently trading at $39.6, will... Sign up to access price prediction.
Disclaimer:
This prediction is provided for informational purposes only and does not constitute financial advice. Market conditions are subject to change, and past performance is not indicative of future results. Please conduct your own research or consult a professional before making investment decisions.
About 0HB0.L
-
Agios Pharmaceuticals, Inc.
-
Symbol
0HB0.L
-
Market
LSE
-
Industry
Medical - Pharmaceuticals
-
Market Cap
2.3B
Similar Stocks
 |
Vertex Pharmaceuticals Incorporated 0QZU.L |
$398.5 0.5% |
7 |
 |
Neurocrine Biosciences 0K6R.L |
$136.1 1.2% |
7 |
 |
Emergent BioSolutions Inc. 0IGA.L |
$9.46 2.9% |
4 |
 |
Abeona Therapeutics Inc. 0H7R.L |
$7.25 1.7% |
5 |
 |
Walgreens Boots Alliance 0LSZ.L |
$12.17 0.5% |
5 |
News
0HB0.L Alternative Data
Web Traffic
Agios Pharmaceuticals receives an estimated 19902 monthly visitors to agios.com.
-
Web Traffic
19902
-
Change from Previous Month
18.7%
-
3 Month Change
3.9%
-
YoY Change
3.9%
Twitter Followers
Agios Pharmaceuticals has 2,674 Twitter Followers on its main Twitter (also known as X) account, which is down by -0% over the last month.
-
Twitter Followers
2674
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0.5%
-
YoY Change
0.5%
Job Postings
Agios Pharmaceuticals has an estimated 15 open job postings, which is down -48.3% over the last month.
-
Job Postings
15
-
Daily Change
0%
-
1 Month Change
48.3%
-
3 Month Change
46.4%
-
YoY Change
46.4%
Reddit Mentions
Agios Pharmaceuticals has been mentioned an estimated 0 times in investment subreddits on Reddit over the last 24 hours.
-
Reddit Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
LinkedIn Followers
91,370 are following Agios Pharmaceuticals on LinkedIn, up by 1.9% over the last month.
-
LinkedIn Followers
91370
-
Daily Change
1.9%
-
1 Month Change
1.9%
-
3 Month Change
4.5%
-
YoY Change
4.5%
LinkedIn Employees
According to LinkedIn, Agios Pharmaceuticals has 652 employees, up by 0.9% over the last month.
-
LinkedIn Employees
652
-
Daily Change
0.9%
-
1 Month Change
0.9%
-
3 Month Change
4.5%
-
YoY Change
4.5%
Business Outlook
According to employee reviews, the business outlook among employees at Agios Pharmaceuticals is 67 out of 100 (bullish).
-
Business Outlook
67
-
Change from Previous Month
0%
-
3 Month Change
0%
-
YoY Change
0%
News Mentions
Agios Pharmaceuticals was mentioned 0 times in the news yesterday.
-
News Mentions
0
-
Daily Change
0%
-
1 Month Change
0%
-
3 Month Change
0%
-
YoY Change
0%
0HB0.L Financials
0HB0.L Key Metrics
-
Total Revenue
$10.7M
-
Net Income
-$96.5M
-
Earnings per Share
-$1.69
-
Free cash flow
-$134.1M
-
EBITDA
-$104M
-
EBITDA Ratio
-9.69543
-
Total Assets
$1.7B
0HB0.L 2-year Revenue & Income
0HB0.L 2-year Free Cash Flow
0HB0.L Technicals
0HB0.L SMA
0HB0.L RSI
FAQ
What's the current price of Agios Pharmaceuticals (0HB0.L) Stock?
The price of an Agios Pharmaceuticals (0HB0.L) share is $39.6.
What's the market cap of Agios Pharmaceuticals?
The current market cap of Agios Pharmaceuticals is 2.3B.
Should I buy or sell 0HB0.L?
Multiple alternative data signals suggest that Agios Pharmaceuticals stock could offer a buying opportunity at its current level, with a reasonable expectation for positive performance in the mid term.
Is Agios Pharmaceuticals a good investment?
Based on an in-depth analysis that encompasses fundamentals, technical analysis, and alternative data insights, it appears to be a favorable time to consider investing in Agios Pharmaceuticals stock. The bullish indicators suggest that Agios Pharmaceuticals' growth prospects and market position may lead to a positive performance in the foreseeable future.
Is now a good time to buy Agios Pharmaceuticals (0HB0.L) Stock?
Based on an analysis that includes fundamentals, technical analysis, and alternative data insights, it could be a favorable time to consider buying Agios Pharmaceuticals stock, given the bullish outlook.
What are some stocks similar to Agios Pharmaceuticals (0HB0.L) that investors often compare it to?
Agios Pharmaceuticals (0HB0.L) is often compared to similar stocks such as Vertex Pharmaceuticals Incorporated, Neurocrine Biosciences, Emergent BioSolutions Inc., Abeona Therapeutics Inc. and Walgreens Boots Alliance.
What is the forecast for Agios Pharmaceuticals' stock price in 2026?
Using a mix of financial analysis, technical indicators, and alternative data, we forecast Agios Pharmaceuticals' stock price to be around $42.64 in 2026. Starting from the current price of $39.6, this represents a 7.7% change in price, indicating a bullish outlook for the stock.
How to buy Agios Pharmaceuticals (0HB0.L) Stock?
Agios Pharmaceuticals stock is available for purchase through numerous brokerage firms, including online platforms. Investors can also buy Agios Pharmaceuticals shares via trading apps on their smartphones or by utilizing services like robo-advisors for automated investing.